Acron Helvetia VII merges with Acron Swiss Premium Assets
The real estate fund Acron Helvetia VII Immobilien AG has entered into a merger agreement with Acron Swiss Premium Assets AG. The fund will be transferred to the AG and dissolved retroactively as of December 31, 2016.
Acron Swiss Premium Assets AG already holds 93.84 percent of the share capital and the
voting rights in the real estate fund. However, the merger still has to be approved by the General Assembly of Acron Helvetia VII and for this purpose an Extraordinary General Assembly will be held on May 2.
The merger is considered approved if at least 90 percent of the shareholders with voting rights agree, Acron says. The fund company's shareholders are to receive a settlement of CHF 95 in cash for one registered share of CHF 60.76 par value.
In addition, the Board of Directors has submitted a delisting request to the BX Berne eXchange.
The investment property of the real estate fund is the seven-story and fully leased Portikon office property at the Glattpark location in Zurich-Opfikon. The atrium building was completed in September 2009. The two main tenants, Baxter Healthcare and Takeda Pharmaceuticals International, together rent approximately 90 percent of the available
standing rental space until 2019.
